Summit Therapeutics (SMMT) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic and Clinical Highlights

• Ivonescimab has completed four positive phase III studies, establishing a leadership position in the PD-1/VEGF space with a potential market exceeding $100 billion annually.

• Fourteen phase III trials are ongoing or announced, with over 4,000 patients enrolled globally and more than 60,000 patients dosed commercially in China.

• Ivonescimab's differentiated mechanism of action and cooperative binding properties drive its efficacy and safety profile, outperforming current PD-1 inhibitors.

• The pipeline includes global phase III trials in non-small cell lung cancer and colorectal cancer, with strategic collaborations expanding into novel combinations.

• Regulatory milestones include a BLA submission to the FDA in Q4 2025, with a decision expected by year-end 2026, and multiple approvals or pending indications in China.

Clinical Trial Results and Competitive Positioning

• Four phase III trials have shown statistically significant, clinically meaningful improvements in progression-free and overall survival across multiple NSCLC settings.

• Ivonescimab demonstrated superiority over Keytruda and other PD-1 inhibitors in head-to-head trials, with consistent efficacy across Eastern and Western populations.

• Safety profile remains manageable, with low rates of discontinuation or death and consistent results across studies.

• The Harmony III trial now covers two patient populations, with key data readouts expected in 2026 and 2027.

• Competitors remain in earlier stages, reinforcing ivonescimab's multi-year head start in key indications.

Partnerships, Pipeline Expansion, and Financials

• Collaborations with Akeso, Revolution Medicines, and GSK are expanding the reach of ivonescimab into new tumor types and combination regimens.

• Over 60 investigator-sponsored trials are supported, with 15 currently enrolling, enhancing the breadth of clinical data.

• Ivonescimab has been featured in 46 scientific presentations and publications, reflecting strong medical community interest.

• Raised $500 million in October, bringing cash reserves to $710 million and maintaining a debt-free position to support ongoing development.

• The addressable market for ivonescimab is estimated at over $100 billion, with significant potential in NSCLC and other solid tumors.